GPCR Structure Therapeutics Inc. - American Depositary Shares
NASDAQ · Pharmaceuticals · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 6, 2026
$27.67
· % 处于52周区间
· 高于低点
· 至高点
$25.5952周低点
$94.9052周高点
市值 (MRQ)
$5.91B
P/E
-34.6
EPS
$-0.80
GPCR 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$27.67
市值 (MRQ)
$5.91B
P/E
-34.6
EPS
$-0.80
ROE
-12.3%
52周区间
$26–$95
GPCR 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
10年表现 收入、净利润、利润率和每股收益趋势
EPS$-0.802022-12-31 → 2025-12-31
自由现金流$-226M2023-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | GPCR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E | -34.65年均值 ≈-57.3 | ≈-57.3 | · | · | |
| 市净率 (MRQ) | 4.45年均值 ≈9.2 | ≈9.2 | 5.9 | 估值过高 | |
| 股价/自由现金流 (TTM) | -26.35年均值 ≈-58.2 | ≈-58.2 | · | · | |
| 市现率 (TTM) | -26.85年均值 ≈-59.3 | ≈-59.3 | · | · | |
| Price / Tangible Book (市净率（有形资产）) | 3.95年均值 ≈9.2 | ≈9.2 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | GPCR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| ROA | -11.3%5年均值 ≈-20.0% | ≈-20.0% | -6.0% | 弱 | |
| ROE | -12.3%5年均值 ≈-18.0% | ≈-18.0% | -12.6% | 持平 | |
| ROIC | -11.7%5年均值 ≈-17.6% | ≈-17.6% | -8.2% | 低于平均水平 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | GPCR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 20.85年均值 ≈22.9 | ≈22.9 | 3.4 | 流动性强 | |
| Quick Ratio (速动比率) | 22.95年均值 ≈22.1 | ≈22.1 | 2.7 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
资本效率 资产周转率、库存周转率、应收账款周转率
此比率组尚无数据
基本面数据不足，尚无法计算此比率组。
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
-152.9%
下次报告
十一月 04, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 4, 2026 | $-0.49 | $-0.41 | -20.8% |
| 2026年3月31日 | 五月 6, 2026 | $-0.35 | $-0.35 | 1.2% |
| 2025年12月31日 | $-1.22 | $-0.47 | -157.1% | |
| 2025年9月30日 | $-1.11 | $-0.36 | -209.7% | |
| 2025年6月30日 | $-1.08 | $-0.28 | -283.9% | |
| 2025年3月31日 | $-0.81 | $-0.23 | -246.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| R&D Expense | $225M | $109M | $70M | $36M | |
| SG&A Expense | $62M | $49M | $33M | $16M | |
| Operating Expenses | $177M | $158M | $103M | $53M | |
| Operating Income | $-177M | $-158M | $-103M | $-53M | |
| Pretax Income | $-141M | $-122M | $-89M | $-51M | |
| Income Tax | $515.0K | $310.0K | $236.0K | $17.0K | |
| Net Income | $-141M | $-123M | $-90M | $-51M | |
| EPS (Basic) | $-0.80 | $-0.78 | $-0.81 | $-5.51 | |
| EPS (Diluted) | $-0.80 | $-0.78 | $-0.81 | $-5.51 | |
| Shares (Basic) | 177,596,000 | 157,922,000 | 110,198,000 | 9,584,000 | |
| Shares (Diluted) | 177,596,000 | 157,922,000 | 110,198,000 | 9,584,000 | |
| EBITDA | $-177M | $-158M | $-103M | · |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $800M | $170M | $130M | $26M | |
| Short-term Investments | $647M | $714M | $338M | $65M | |
| Prepaid Expense | $24M | $8M | $6M | $2M | |
| Current Assets | $1.57B | $891M | $474M | $93M | |
| PP&E (Net) | $7M | $3M | $3M | $1M | |
| PP&E (Gross) | $10M | $5M | $4M | $1M | |
| Accum. Depreciation | $3M | $2M | $644.0K | $349.0K | |
| Other Non-current Assets | $717.0K | $5M | $45.0K | $3M | |
| Total Assets | $1.58B | $903M | $482M | $98M | |
| Accounts Payable | $14M | $8M | $5M | $6M | |
| Current Liabilities | $63M | $36M | $25M | $13M | |
| Capital Leases | $4M | $2M | $4M | · | |
| Other Non-current Liabilities | $647.0K | $302.0K | $298.0K | · | |
| Total Liabilities | $68M | $38M | $29M | $13M | |
| Common Stock | $21.0K | $17.0K | $14.0K | $1.0K | |
| Paid-in Capital | $1.99B | $1.19B | $659M | $2M | |
| Retained Earnings | $-470M | $-329M | $-207M | $-117M | |
| AOCI | $1M | $914.0K | $521.0K | $-110.0K | |
| Stockholders' Equity | $1.52B | $865M | $453M | $-115M | |
| Liabilities + Equity | $1.58B | $903M | $482M | $98M | |
| Shares Outstanding | 212,513,000 | 171,860,000 | 139,220,000 | 10,527,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Stock-based Comp | $29M | $19M | $8M | $3M | |
| Operating Cash Flow | $-222M | $-117M | $-79M | $-46M | |
| CapEx | $4M | $1M | $2M | $155.0K | |
| Investing Cash Flow | $90M | $-359M | $-268M | $-62M | |
| Stock Issued | · | $515M | · | · | |
| Net Stock Activity | · | $515M | · | · | |
| Financing Cash Flow | $763M | $515M | $452M | $29M | |
| Net Change in Cash | $630M | $40M | $104M | $-79M | |
| Taxes Paid | $634.0K | $370.0K | $12.0K | · | |
| Free Cash Flow | $-226M | $-118M | $-82M | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| ROA | -11.3% | -17.7% | -30.9% | · | |
| ROE | -12.3% | -13.9% | -27.8% | · | |
| ROIC | -11.7% | -18.3% | -22.8% | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 24.8 | 24.7 | 19.1 | · | |
| Quick Ratio | 22.9 | 24.5 | 18.9 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $7.14 | $5.03 | $3.25 | · | |
| Cash Flow / Share | $-1.25 | $-0.74 | $-0.72 | · | |
| Cash / Share | $3.76 | $0.99 | $0.93 | · | |
| EPS (TTM) | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Net Income TTM | $-141M | $-123M | $-90M | $-51M | |
| Market Cap | $14.78B | $4.66B | $5.67B | · | |
| P/E | -86.9 | -34.8 | -50.3 | · | |
| P/B | 9.7 | 5.4 | 12.5 | · | |
| P / Tangible Book | 9.7 | 5.4 | 12.5 | · | |
| P / Cash Flow | -66.5 | -40.0 | -71.4 | · | |
| P / FCF | -65.5 | -39.5 | -69.5 | · | |
| Earnings Yield | -1.1% | -2.9% | -2.0% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $100M | $67M | $69M | $59M | $55M | $43M | $33M | $33M | $22M | $21M | $18M | $19M | $13M | $8M | $9M | $10M | |
| SG&A Expense | $19M | $23M | $18M | $15M | $16M | $13M | $14M | $13M | $11M | $11M | $9M | $7M | $7M | $5M | $4M | $4M | |
| Operating Expenses | $119M | $89M | $-24M | $74M | $70M | $56M | $47M | $46M | $33M | $32M | $26M | $26M | $20M | $13M | $13M | $14M | |
| Operating Income | $-119M | $-89M | $24M | $-74M | $-70M | $-56M | $-47M | $-46M | $-33M | $-32M | $-26M | $-26M | $-20M | $-13M | $-13M | $-14M | |
| Pretax Income | $-106M | $-76M | $33M | $-66M | $-62M | $-47M | $-36M | $-34M | $-26M | $-26M | $-23M | $-23M | $-18M | $-12M | $-12M | $-14M | |
| Income Tax | $234.0K | $190.0K | $170.0K | $108.0K | $139.0K | $98.0K | $136.0K | $92.0K | $53.0K | $29.0K | $405.0K | $118.0K | $25.0K | $-180.0K | $73.0K | $64.0K | |
| Net Income | $-106M | $-76M | $33M | $-66M | $-62M | $-47M | $-36M | $-34M | $-26M | $-26M | $-24M | $-23M | $-18M | $-12M | $-12M | $-14M | |
| EPS (Basic) | $-0.49 | $-0.35 | $0.20 | $-0.37 | $-0.36 | $-0.27 | $-0.21 | $-0.20 | $-0.18 | $-0.19 | $-0.21 | $-0.20 | $-0.25 | $-1.16 | $-1.27 | $-1.64 | |
| EPS (Diluted) | $-0.49 | $-0.35 | $0.20 | $-0.37 | $-0.36 | $-0.27 | $-0.21 | $-0.20 | $-0.18 | $-0.19 | $-0.21 | $-0.20 | $-0.25 | $-1.16 | $-1.27 | $-1.64 | |
| Shares (Basic) | 217,957,000 | 217,326,000 | · | 175,469,000 | 172,647,000 | 172,051,000 | · | 171,630,000 | 148,239,000 | 139,710,000 | 114,948,000 | 114,759,000 | 71,655,000 | · | 9,780,000 | 9,435,000 | |
| Shares (Diluted) | 217,957,000 | 217,326,000 | · | 175,469,000 | 172,647,000 | 172,051,000 | · | 171,630,000 | 148,239,000 | 139,710,000 | 114,948,000 | 114,759,000 | 71,655,000 | · | 9,780,000 | 9,435,000 | |
| EBITDA | $-119M | $-89M | · | $-74M | $-70M | $-56M | · | $-46M | $-33M | $-32M | $-26M | $-26M | $-20M | · | · | · |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $273M | $316M | $800M | $103M | $147M | $152M | $170M | $172M | $382M | $98M | $51M | $41M | $126M | $26M | · | · | |
| Short-term Investments | $1.07B | $1.14B | $647M | $696M | $639M | $685M | $714M | $743M | $545M | $339M | $155M | $184M | $114M | $65M | · | · | |
| Prepaid Expense | $29M | $32M | $24M | $15M | $13M | $13M | $8M | $8M | $11M | $13M | $5M | $4M | $5M | $2M | · | · | |
| Current Assets | $1.37B | $1.49B | $1.57B | $814M | $799M | $850M | $891M | $924M | $938M | $449M | $210M | $228M | $246M | $93M | · | · | |
| PP&E (Net) | $6M | $6M | $7M | $5M | $3M | $4M | $3M | $4M | $3M | $3M | $2M | $1M | $961.0K | $1M | · | · | |
| PP&E (Gross) | · | · | $10M | · | · | · | $5M | $5M | $4M | $4M | $3M | $2M | $1M | $1M | · | · | |
| Accum. Depreciation | · | · | $3M | · | · | · | $2M | $1M | $1M | $866.0K | $572.0K | $493.0K | $419.0K | $349.0K | · | · | |
| Other Non-current Assets | $41M | $6M | $717.0K | $7M | $6M | $6M | $5M | $2M | $2M | $47.0K | $350.0K | $38.0K | $59.0K | $3M | · | · | |
| Total Assets | $1.43B | $1.51B | $1.58B | $832M | $816M | $867M | $903M | $933M | $947M | $457M | $216M | $229M | $247M | $98M | · | · | |
| Accounts Payable | $11M | $8M | $14M | $18M | $9M | $9M | $8M | $8M | $2M | $7M | $3M | $6M | $5M | $6M | · | · | |
| Current Liabilities | $66M | $57M | $63M | $58M | $39M | $36M | $36M | $33M | $23M | $24M | $20M | $15M | $11M | $13M | · | · | |
| Capital Leases | $4M | $3M | $4M | $4M | $5M | $5M | $2M | $3M | $3M | $4M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $1M | $863.0K | $647.0K | $325.0K | $317.0K | $308.0K | $302.0K | $309.0K | $293.0K | $296.0K | $281.0K | · | · | · | · | · | |
| Total Liabilities | $71M | $61M | $68M | $62M | $44M | $42M | $38M | $36M | $26M | $27M | $23M | $15M | $11M | $13M | · | · | |
| Common Stock | $21.0K | $21.0K | $21.0K | $18.0K | $17.0K | $17.0K | $17.0K | $17.0K | $17.0K | $14.0K | · | · | $11.0K | $1.0K | · | · | |
| Paid-in Capital | $2.01B | $2.00B | $1.99B | $1.27B | $1.21B | $1.20B | $1.19B | $1.19B | $1.18B | $663M | $375M | $373M | $371M | $2M | · | · | |
| Retained Earnings | $-652M | $-546M | $-470M | $-503M | $-438M | $-376M | $-329M | $-293M | $-259M | $-233M | $-182M | $-158M | $-135M | $-117M | · | · | |
| AOCI | $-3M | $-2M | $1M | $825.0K | $362.0K | $815.0K | $914.0K | $3M | $-487.0K | $-90.0K | $-310.0K | $-390.0K | $147.0K | $-110.0K | · | · | |
| Stockholders' Equity | $1.35B | $1.45B | $1.52B | $770M | $772M | $825M | $865M | $897M | $921M | $430M | $193M | $214M | $236M | $-115M | · | · | |
| Liabilities + Equity | $1.43B | $1.51B | $1.58B | $832M | $816M | $867M | $903M | $933M | $947M | $457M | $216M | $229M | $247M | $98M | · | · | |
| Shares Outstanding | 213,655,000 | 213,208,000 | 212,513,000 | 182,033,000 | 172,700,000 | 172,610,000 | 171,860,000 | 171,762,000 | 171,589,000 | 139,855,000 | · | · | 114,730,000 | 10,527,000 | · | · |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $13M | $12M | $8M | $7M | $8M | $6M | $6M | $6M | $4M | $3M | $2M | $2M | $3M | $623.0K | $628.0K | $643.0K | |
| Operating Cash Flow | $-120M | $15M | $-64M | $-51M | $-55M | $-52M | $-36M | $-20M | $-26M | $-34M | $-21M | $-17M | $-20M | $-12M | $-10M | $-10M | |
| CapEx | $-42.0K | $1M | $1M | $2M | $232.0K | $314.0K | $16.0K | $685.0K | $427.0K | $162.0K | $820.0K | · | · | $71.0K | $72.0K | $-53.0K | |
| Investing Cash Flow | $74M | $-497M | $56M | $-49M | $49M | $34M | $33M | $-189M | $-205M | $1M | $30M | $-69M | $-49M | $10M | $-17M | $-16M | |
| Stock Issued | · | · | · | · | · | · | · | $0 | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $2M | $-2M | $705M | $56M | $517.0K | $809.0K | $615.0K | $-757.0K | $515M | $702.0K | $473.0K | $-297.0K | $170M | $-316.0K | $-259.0K | $31M | |
| Net Change in Cash | $-44M | $-483M | $697M | $-44M | $-5M | $-17M | $-3M | $-209M | $284M | $-32M | $10M | $-86M | $100M | $-2M | $-27M | $5M | |
| Free Cash Flow | · | $14M | · | · | · | $-53M | · | · | · | $-34M | · | · | · | · | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -9.5% | -6.4% | · | -7.4% | -7.0% | -7.1% | · | -5.9% | -4.4% | -7.4% | -22.1% | · | -14.5% | · | · | · | |
| ROE | -10.0% | -6.7% | · | -7.9% | -7.3% | -7.5% | · | -6.2% | -4.6% | -7.8% | -24.7% | · | -15.2% | · | · | · | |
| ROIC | -8.8% | -6.2% | · | -9.6% | -9.2% | -6.8% | · | -5.1% | -3.6% | -7.5% | -13.8% | -12.2% | -8.3% | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.8 | 26.2 | · | 14.2 | 20.5 | 23.3 | · | 27.6 | 41.4 | 19.1 | 10.5 | 15.2 | 22.4 | · | · | · | |
| Quick Ratio | 20.3 | 25.6 | · | 13.9 | 20.1 | 22.9 | · | 27.4 | 40.9 | 18.5 | 10.2 | 15.0 | 21.9 | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.34 | $6.79 | · | $4.23 | $4.47 | $4.78 | · | $5.22 | $5.37 | $3.07 | · | · | $2.06 | · | · | · | |
| Cash Flow / Share | · | $0.07 | · | · | · | $-0.30 | · | · | · | $-0.24 | · | · | $-0.28 | · | · | · | |
| Cash / Share | $1.28 | $1.48 | · | $0.57 | $0.85 | $0.88 | · | $1.00 | $2.22 | $0.70 | · | · | $1.10 | · | · | · | |
| EPS (TTM) | $-1.01 | $-0.88 | · | $-1.21 | $-1.04 | $-0.86 | · | $-0.72 | $-0.73 | $-0.75 | $-1.82 | $-2.88 | $-4.32 | · | · | · |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-215M | $-170M | · | $-211M | $-179M | $-143M | · | $-111M | $-100M | $-98M | $-77M | $-66M | $-56M | · | · | · | |
| Market Cap | $11.47B | $10.28B | · | $5.10B | $3.58B | $2.99B | · | $7.54B | $6.74B | $5.99B | · | · | $2.73B | · | · | · | |
| P/E | -53.1 | -54.8 | · | -23.1 | -19.9 | -20.1 | · | -61.0 | -53.8 | -57.1 | -27.7 | -14.4 | -5.5 | · | · | · | |
| P/B | 8.5 | 7.1 | · | 6.6 | 4.6 | 3.6 | · | 8.4 | 7.3 | 13.9 | · | · | 11.5 | · | · | · | |
| P / Tangible Book | 8.5 | 7.1 | · | 6.6 | 4.6 | 3.6 | · | 8.4 | 7.3 | 13.9 | · | · | 11.5 | · | · | · | |
| P / Cash Flow | · | 674.6 | · | · | · | -57.2 | · | · | · | -175.9 | · | · | -134.4 | · | · | · | |
| Earnings Yield | -1.9% | -1.8% | · | -4.3% | -5.0% | -5.0% | · | -1.6% | -1.9% | -1.8% | -3.6% | -6.9% | -18.2% | · | · | · |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| 净收入 | $-141M | $-123M | $-90M | $-51M |
| 稀释后每股收益 (EPS) | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| 流动比率 | 24.8 | 24.7 | 19.1 | · |
| 速动比率 | 22.9 | 24.5 | 18.9 | · |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| 自由现金流 | $-226M | $-118M | $-82M | · |
机构持有人 (13F) 204 家申报者 · $3.6B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
204
持有价值
$3.6B
新仓位
31
已退出持仓
28
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 31 (-8 与上一季度对比) | 28 (-10 与上一季度对比) | 75 (+4 与上一季度对比) | 55 (-11 与上一季度对比) | -4.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| FMR LLC | $419179123 | 7810306 | 11.69% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $396054169 | 7379433 | 11.05% | 股份 |
| Avoro Capital Advisors LLC | $351836637 | 6555555 | 9.81% | 股份 |
| JANUS HENDERSON GROUP PLC | $258260143 | 5354981 | 7.20% | 股份 |
| Deep Track Capital, LP | $254399664 | 4740072 | 7.10% | 股份 |
| BVF INC/IL | $180697390 | 3366823 | 5.04% | 股份 |
| MORGAN STANLEY | $150632372 | 2806640 | 4.20% | 股份 |
| ORBIMED ADVISORS LLC | $118578498 | 2209400 | 3.31% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $94070254 | 1752753 | 2.62% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $90282956 | 1682179 | 2.52% | 股份 |
| RTW INVESTMENTS, LP | $86274901 | 1607507 | 2.41% | 股份 |
| Driehaus Capital Management LLC | $83361264 | 1553219 | 2.33% | 股份 |
| BAKER BROS. ADVISORS LP | $76883831 | 1432529 | 2.14% | 股份 |
| Casdin Capital, LLC | $63062250 | 1175000 | 1.76% | 股份 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $58285620 | 1086000 | 1.63% | 股份 |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $55875837 | 1041100 | 1.56% | 股份 |
| Siren, L.L.C. | $46852139 | 872967 | 1.31% | 股份 |
| Pacific Heights Asset Management LLC | $42936000 | 800000 | 1.20% | 股份 |
| Rock Springs Capital Management LP | $34365813 | 640317 | 0.96% | 股份 |
| Aberdeen Group plc | $34344238 | 639915 | 0.96% | 股份 |
| FRANKLIN RESOURCES INC | $31066308 | 578839 | 0.87% | 股份 |
| BANK OF AMERICA CORP /DE/ | $30238858 | 563422 | 0.84% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $29484326 | 611708 | 0.82% | 股份 |
| BlackRock, Inc. | $27433368 | 511149 | 0.77% | 股份 |
| Logos Global Management LP | $26835000 | 500000 | 0.75% | 股份 |
| Parkman Healthcare Partners LLC | $26065426 | 485661 | 0.73% | 股份 |
| Davern Capital Partners, LP | $23939987 | 446059 | 0.67% | 股份 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $22476996 | 418800 | 0.63% | 股份 |
| UBS Group AG | $20340179 | 378986 | 0.57% | 股份 |
| DEUTSCHE BANK AG\ | $17811302 | 331867 | 0.50% | 股份 |
| NEXTBio Capital Management LP | $16771660 | 312496 | 0.47% | 股份 |
| Catalio Capital Management, LP | $14842438 | 276550 | 0.41% | 股份 |
| MARSHALL WACE, LLP | $14361663 | 267592 | 0.40% | 股份 |
| HSG Holding Ltd | $14279548 | 266062 | 0.40% | 股份 |
| SEB Asset Management AB | $13151433 | 245043 | 0.37% | 股份 |
| GOLDMAN SACHS GROUP INC | $13030539 | 242790 | 0.36% | 股份 |
| AMERIPRISE FINANCIAL INC | $12371685 | 230514 | 0.35% | 股份 |
| NATIONAL BANK OF CANADA /FI/ | $11581986 | 215800 | 0.32% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $10957053 | 204156 | 0.31% | 股份 |
| Eversept Partners, LP | $10535528 | 196302 | 0.29% | 股份 |
| Schonfeld Strategic Advisors LLC | $10234062 | 190685 | 0.29% | 股份 |
| Woodline Partners LP | $8254875 | 153808 | 0.23% | 股份 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $8218000 | 153119 | 0.23% | 股份 |
| ArrowMark Colorado Holdings LLC | $8081575 | 150579 | 0.23% | 股份 |
| Susquehanna Portfolio Strategies, LLC | $7994039 | 148948 | 0.22% | 股份 |
| CenterBook Partners LP | $7944770 | 148030 | 0.22% | 股份 |
| Rhenman & Partners Asset Management AB | $7787517 | 145100 | 0.22% | 股份 |
| GOLDMAN SACHS GROUP INC | $7782150 | 145000 | 0.22% | 买入期权 |
| B Group, Inc. | $7513800 | 140000 | 0.21% | 股份 |
| HighVista Strategies LLC | $7019177 | 130784 | 0.20% | 股份 |
公司内部人士 19 位内幕人士 · 10 位高管 · 8 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Raymond C Stevens | CHIEF EXECUTIVE OFFICER | 2026年3月19日 A | 1401593 | 0 | 0 | $0 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | 2026年3月19日 A | 1401656 | 0 | 0 | $0 |
| Matthew Lang | COO & GC | 2026年4月15日 A | 184614 | 0 | 0 | $0 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | 2026年9月21日 S | 258228 | 0 | 1 | $-144889 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2026年9月1日 S | 228960 | 0 | 11 | $-1472329 |
| John Joseph Berrios | Chief Commercial Officer | 2026年8月6日 A | 140766 | 0 | 0 | $0 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | 2026年3月19日 A | 139917 | 0 | 0 | $0 |
| Ashley Hall | Chief Development Officer | 2026年3月19日 A | 155187 | 0 | 0 | $0 |
| Mark Allen Bach | CHIEF MEDICAL OFFICER | 2024年3月15日 A | 26235 | 0 | 0 | $0 |
| Melita Sun Jung | Chief Business Officer | 2023年2月7日 P | · | 0 | 0 | $0 |
| Joanne Waldstreicher | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Angus C. Russell | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Sharon Tetlow | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Daniel G Welch | 董事 | 2026年6月17日 A | 123508 | 0 | 0 | $0 |
| Eric Dobmeier | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Ted W Love | 董事 | 2026年6月17日 A | · | 0 | 0 | $0 |
| Ramy Farid | 董事 | 2023年2月7日 P | 3260495 | 0 | 0 | $0 |
| FMR LLC | 10% 所有者 | 2026年7月22日 S | 4769404 | 0 | 22 | $-7057088 |
| FIL Ltd | · | 2023年2月7日 C | 624239 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 4 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
GPCR 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 23 位分析师
买入
中位数目标
$101.00
+265.0%
8 34.8%
强烈买入
13 56.5%
买入
2 8.7%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
15 位分析师 · 2026-10-02平均目标 $105.78 +282.3%
← 低于所有目标
当前价格 $27.67
最低$70.00
平均值$105.78
最高$145.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| GPCR | $14.78B | -86.9 | · | · | -12.3% | · |
| AMRX | · | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| HRMY | $2.16B | 13.8 | 21.5% | 18.3% | 19.3% | 77.2% |
| PBH | $3.33B | 15.2 | -4.3% | 17.5% | 10.2% | 54.7% |
| TRLV | · | · | -0.45% | -10.3% | -10.4% | 60.2% |
| TRVI | $1.61B | -39.1 | · | · | -22.4% | · |
| NUVB | $3.03B | -14.9 | 699.0% | -325.3% | -60.3% | · |
| SEPN | $1.25B | -25.3 | 4174.5% | -106.4% | -12.9% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报